NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study
https://www.nodthera.com/nodthera-announces-progress-of-nt-0796-a-novel-nlrp3-inflammasome-inhibitor-into-a-phase-1-first-in-human-study/
https://www.linkedin.com/posts/nodthera-limited_clinicaltrial-inflammasome-biotechnews-activity-6862010617897779201-yLyf